Lintuzumab Biosimilar - Research Grade

Human

CD33ï؟½

5mg/ml

IgG1 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

P20138

Blue ice

CD33 is a myeloid-restricted siglec broadly expressed on leukemic blasts, making it a long-standing target in acute myeloid leukemia research. Built on a human IgG1, kappa framework, this reagent is an unconjugated, non-therapeutic analog of lintuzumab that binds CD33 for functional assays. It is formulated to low-endotoxin specifications appropriate for in vivo experiments and produced in scalable milligram-to-gram lots that meet the needs of bulk and high-throughput laboratories. Provided for research use only (RUO), it serves as a control and active probe in myeloid-cell targeting studies, internalization and ADCC assays, in vitro screening, and preclinical leukemia models.

SIGLEC3

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks